Table 1.
Patient characteristics by anticoagulation at baseline.
|
VKA (n = 76) |
DOAC (n = 234) |
p-Value | |
|---|---|---|---|
| Demographics | |||
| Age, years (mean) [SD] | 79.4 [9.1] | 77.7 [9.2] | 0.172 |
| Sex = male, n (%) | 35 (46.1) | 132 (56.4) | 0.149 |
| Medication | |||
| Only DOACs, n (%) | – | 216 (92.3) | |
| DOACs/antiplatelet, n (%) | – | 18 (7.7) | |
| Only VKAs, n (%) | 61 (80.3) | – | |
| VKAs/antiplatelet, n (%) | 15 (19.7) | – | |
| Vascular risk factors | |||
| Hypertension, n (%) | 61 (80.3) | 175 (74.8) | 0.413 |
| Diabetes, n (%) | 15 (19.7) | 47 (20.1) | 1.000 |
| Hyperlipidemia, n (%) | 31 (40.8) | 89 (38.0) | 0.770 |
| Kidney function, GFR (CKD-EPI: ml/min/1.7) [SD] | 59.1 [23.7] | 70.2 [18.3] | <0.001 |
| Smoking, n (%) | 5 (6.6) | 15 (6.4) | 0.822 |
| Alcohol consumption, n (%) | 5 (6.6) | 17 (7.3) | 0.816 |
| NIHSS at baseline (median [IQR]) | 4.0 [2.0, 7.2] | 3.0 [1.0, 7.0] | 0.447 |
| Follow-up time, days (median [IQR]) | 740 [645; 821] | 716.5 [179; 784] | |
| Microbleeds, n (%) | 20 (26.3) | 66 (28.2) | 0.863 |
| Superficial | 13 (17.1) | 41 (17.5) | |
| Deep | 13 (17.1) | 37 (15.8) | |
| Cerebellum | 8 (10.5) | 15 (6.4) | |
| Brainstem | 4 (5.3) | 9 (3.8) | |
SD, Standardized difference; VKAs, Vitamin K antagonists; DOAC, direct oral anticoagulants; GFR, glomerular infiltration rate.